CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (123/131I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors

CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (123/131I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors

Abstract Background Neuroblastoma (NB) and pheochromocytoma/paraganglioma (PHEO/PGL) are neuroendocrine tumors. Imaging of these neoplasms is performed by scintigraphy after injection of radiolabeled meta-iodobenzylguanidine (mIBG), a norepinephrine analog taken up by tumoral cells through monoamine...

Full description

Bibliographic Details
Main Authors: Joana Grand-Guillaume, Rosalba Mansi, Raghuvir H. Gaonkar, Sandra Zanger, Melpomeni Fani, Philippe J. Eugster, Maja Beck Popovic, Eric Grouzmann, Karim Abid
Format: Article
Language:English
Published: BMC 2023-09-01
Series:Journal of Translational Medicine
Subjects:
Neuroendocrine tumors
Theranostics
Meta-iodobenzylguanidine (mIBG)
Histone deacetylase inhibitor (HDACi)
PI3K/AKT/mTOR inhibitor
Xenograft
Online Access:https://doi.org/10.1186/s12967-023-04466-z

Internet

https://doi.org/10.1186/s12967-023-04466-z

Similar Items